Breaking News Instant updates and real-time market news.

FB

Facebook

$192.56

1.4 (0.73%)

, CZR

Caesars

$11.43

1.44 (14.41%)

07:35
06/25/19
06/25
07:35
06/25/19
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Monday in Facebook (FB), Caesars (CZR), Dominion (D), Mallinckrodt (MNK), Norwegian Cruise Line (NCLH), Karyopharm (KPTI), and Laureate Education (LAUR).

FB

Facebook

$192.56

1.4 (0.73%)

CZR

Caesars

$11.43

1.44 (14.41%)

D

Dominion

$79.22

0.88 (1.12%)

MNK

Mallinckrodt

$8.42

-0.54 (-6.03%)

NCLH

Norwegian Cruise Line

$50.84

-0.29 (-0.57%)

KPTI

Karyopharm

$6.35

-0.085 (-1.32%)

LAUR

Laureate Education

$15.00

-0.365 (-2.38%)

  • 25

    Jun

  • 02

    Jul

  • 06

    Jul

  • 10

    Jul

  • 16

    Jul

FB Facebook
$192.56

1.4 (0.73%)

06/24/19
CLVD
06/24/19
NO CHANGE
CLVD
Google partners moderating outlooks, says Cleveland Research
Cleveland Research said its checks indicate that partners of Google (GOOGL) are moderating their 2019 outlooks, citing slowing growth in Search, less contribution from YouTube due to brand-safety concerns and some share loss to Amazon (AMZN) and Facebook (FB). The firm's research suggests Q2 advertising budgets at Google may be moderating further compared to Q1 trends, Cleveland Research told investors.
06/24/19
OPCO
06/24/19
NO CHANGE
Target $225
OPCO
Outperform
Oppenheimer remains bullish on Facebook ahead of Q2 results
Oppenheimer analyst Jason Helfstein remains bullish on Facebook shares ahead of Q2 results. Despite the seemingly ever-present regulation threat, engagement and monetization appear strong, he contends. The analyst notes that agency checks suggest news headlines are having no impact on advertisers client spending, so long as conversion and ROI remain strong. Meanwhile, 3P data remains bullish, suggesting engagement remains healthy, he adds. Lastly, Helfstein points out that a deeper look into CCPA shows that it may have a weaker than expected effect, and thinks Facebook is prepared and should experience less turbulence than previously expected. The analyst reiterates an Outperform rating and $225 price target on the shares.
06/19/19
RHCO
06/19/19
NO CHANGE
Target $215
RHCO
Buy
Facebook Libra initiative to 'disrupt financial services', says SunTrust
SunTrust analyst Youssef Squali kept his Buy rating and $215 price target on Facebook after its white paper release on its intended launch of the Libra blockchain currency platform that would offer "access to better and cheaper financial services worldwide." The analyst notes that since the platform would likely take "several years to develop", he is not changing any of its near-term financial estimates for the company. Nonetheless, Squali contends that Libra represents a "major initiative for Facebook", with potential to put it front and center in areas beyond advertising and including commerce and financial services toward "material" expansion of its total addressable market and growth prospects.
06/19/19
MSCO
06/19/19
NO CHANGE
MSCO
Visa, MasterCard disruption threat from Libra 'fairly low,' says Morgan Stanley
After Facebook (FB) unveiled its cryptocurrency Libra yesterday, Morgan Stanley analysts led by Brian Nowak highlighted six "key questions" they still have about the impact on Facebook, commerce and the overall global banking and payments system from the social media giant's offering. The team, as previously stated, believe that Instagram commerce could be a greater than $4B annual opportunity for Facebook and even larger over the long term across Instagram, Messenger, WhatsApp and the core app. However, they also think costs may rise as they believe Facebook is likely going to have to fund rewards to drive Libra adoption. Libra's real-time aspect largely already exists in the banking system, except for in real-time cross-border payments, which is a challenge that Facebook could address, though it won't be alone there as JPMorgan (JPM) is also working on its own s Interbank Information Network blockchain, the team noted. The team believes Libra's threat of disruption to Visa (V) and Mastercard (MA) is "fairly low" as the major networks have a significant scale advantage, low costs, mature fraud detection abilities and they are both also founding members and investors, Nowak and the analysts also noted.
CZR Caesars
$11.43

1.44 (14.41%)

06/25/19
RHCO
06/25/19
DOWNGRADE
Target $12.75
RHCO
Hold
Caesars downgraded to Hold from Buy at SunTrust
SunTrust analyst Barry Jonas downgraded Caesars (CZR) to Hold from Buy with a $12.75 price target following its agreement to be acquired by Eldorado Resorts (ERI). In a research note to investors, Jonas says he met with Eldorado CEO and CFO following the announcement, and says he left "positive" on the deal despite the share reaction, which he thinks was likely arb driven. Looking ahead, he says management appears "confident" in hitting their $500M synergy target with potentially meaningful upside.
06/25/19
NOMU
06/25/19
DOWNGRADE
NOMU
Neutral
Caesars downgraded to Neutral from Buy at Nomura Instinet
05/29/19
DBAB
05/29/19
NO CHANGE
DBAB
Deutsche Bank sees increased odds of Eldorado, Caesars merger
Deutsche Bank analyst Carlo Santarelli believes the likelihood for an Eldorado Resorts (ERI) / Caesars Entertainment (CZR) pairing has increased and that the transaction would be a net positive for both companies as well as the gaming group. The analyst would be buyers of both stocks at current levels. Strengthening same-store fundamentals and continued M&A activity in the coming months should drive increased investor interest in the gaming group, Santarelli tells investors in a research note.
03/20/19
JPMS
03/20/19
NO CHANGE
Target $60
JPMS
Overweight
Eldorado shares could be worth $72-$80 with Caesars deal, says JPMorgan
JPMorgan analyst Daniel Politzer estimates that an Eldorado Resorts (ERI) acquisition of Caesars Entertainment (CZR) could generate $300M in synergies, imply a valuation of $72-$80 per share, and be ~50% accretive on a free cash flow per share basis. Reuters reported over the weekend that the two companies are in merger talks. The analyst's scenario contemplates Eldorado acquiring Caesars for $10.50 per share, or a 23% premium to last night's close, with the offer consisting of $6.25 in cash and $4.25 worth of stock. Politzer keeps an Overweight rating on Eldorado Resorts with a $60 price target.
D Dominion
$79.22

0.88 (1.12%)

06/13/19
06/13/19
UPGRADE
Target $80

Neutral
Dominion upgraded to Neutral on valuation at BofA/Merrill
As previously reported, BofA/Merrill upgraded Dominion to Neutral from Underperform with an $80 price target. Analyst Julien Dumoulin-Smith said risk/reward is more balanced and factors in the risks associated with Atlantic Coast Pipeline.
03/18/19
MACQ
03/18/19
DOWNGRADE
MACQ
Neutral
Dominion downgraded to Neutral from Outperform at Macquarie
06/04/19
KEYB
06/04/19
INITIATION
KEYB
Sector Weight
Dominion initiated with a Sector Weight at KeyBanc
KeyBanc analyst Sophie Karp started Dominion with a Sector Weight rating. While the stock's story is much "cleaner" with a number of overhangs removed, the analyst still sees multiple issues remaining, including regulatory challenges.
06/13/19
BOFA
06/13/19
UPGRADE
BOFA
Neutral
Dominion upgraded to Neutral from Underperform at BofA/Merrill
MNK Mallinckrodt
$8.42

-0.54 (-6.03%)

06/14/19
ADAM
06/14/19
NO CHANGE
Target $22
ADAM
Buy
Mallinckrodt price target lowered to $22 from $37 at Canaccord
Canaccord analyst Dewey Steadman lowered his price target on Mallinckrodt to $22 from $37 following the company's release of a blinded RA study showing Acthar's effectiveness. The analyst noted the data is the first of a string of expected Acthar data reads that he thinks can bolster and justify Acthar's use for exacerbations in highly refractory immune-modulated conditions. The price target reduction is based on a lower expected contribution from pipeline products. Steadman maintained his Buy rating on Mallinckrodt shares.
06/11/19
LEHM
06/11/19
INITIATION
Target $11
LEHM
Equal Weight
Mallinckrodt initiated with an Equal Weight at Barclays
Barclays analyst Balaji Prasad started Mallinckrodt with an Equal Weight rating and $11 price target. The analyst launched coverage of 20 U.S. Specialty Pharmaceuticals with a Neutral industry view. He placed importance on cash flows and companies' ability to manage leverage and improve balance sheets.
06/12/19
CANT
06/12/19
NO CHANGE
Target $18
CANT
Overweight
Mallinckrodt price target lowered to $18 from $42 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen lowered her price target for Mallinckrodt to $18 from $42, driven by multiple contraction, given increasing headwinds from macro factors. While acknowledging that competition for Acthar could drive downside to her estimates and the consensus, the analyst reiterates an Overweight rating on the shares.
06/13/19
STFL
06/13/19
NO CHANGE
Target $24
STFL
Hold
Mallinckrodt's Acthar Phase 4 data shows 'strong' evidence in RA, says Stifel
Stifel analyst Annabel Samimy maintained a Hold rating and $24 price target on Mallinckrodt after the company released the full release of its two-part Phase 4 study of Acthar in refractory patients with persistent Rheumatoid Arthritis at EULAR, noting that both parts of the study hit all primary and secondary endpoints. In a research note to investors, Samimy says with these data that show "strong" clinical evidence in RA, she sees opportunity for Mallinckrodt to have more meaningful clinical discussions in third-party payer negotiations and greater validation with Medicare, both of which could support Acthar volumes going forward.
NCLH Norwegian Cruise Line
$50.84

-0.29 (-0.57%)

06/20/19
WBLR
06/20/19
DOWNGRADE
WBLR
Market Perform
William Blair downgrades Carnival with yields underperforming peers
William Blair analyst Sharon Zackfia downgraded Carnival (CCL) to Market Perform from Outperform following this morning's Q2 results. The company lowered expectations for the remainder of the fiscal year, with constant-currency net yields now expected to be flattish to slightly down in Q3 and down in Q4, translating to full-year net yields of flat versus prior guidance of up approximately 1%, Zackfia tells investors in a research note. She points out that Carnival's flattish yield expectation compares to underlying guidance for mid-single-digit gains at Royal Caribbean (RCL) and Norwegian Cruise Line (NCLH). The analyst attributes Carnival's underperformance to its nationalistic brands and greater exposure to Europe. The ongoing geopolitical uncertainty in Europe and today's lowered guidance is likely to put the stock in a "show-me state and limit shareholder returns," Zackfia contends.
06/21/19
LEHM
06/21/19
DOWNGRADE
Target $55
LEHM
Equal Weight
Carnival downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Felicia Hendrix downgraded Carnival (CCL) to Equal Weight from Overweight and lowered her price target for the shares to $55 from $69. The company's challenges in Europe, which could continue into next year, make it difficult to justify the sane Overweight rating that is on peers Royal Caribbean (RCL) and Norwegian Cruise Line (NCLH), Hendrix tells investors in a research note. She believes the two peers "face stronger growth catalysts" than Carnival. As such, Carnival shares will continue to underperform, says Hendrix.
06/21/19
STFL
06/21/19
NO CHANGE
Target $71
STFL
Buy
Norwegian Cruise pullback on Carnival earnings a buying opportunity, says Stifel
Stifel analyst Steven Wieczynski said he believes Norwegian Cruise Line (NCLH) seems immune to some of the Alaska and European issues pressuring others in the industry and that its overall business continues to perform solidly. After recently having spent time with the management team, he remains confident in their ability to deliver on the objectives laid out at their 2018 analyst day and he believes the pullback in the stock following yesterday's earnings report disappointment from Carnival (CCL) presents investors with a "great time to build positions in the name," Wieczynski said. He keeps a Buy rating and $71 target price on Norwegian Cruise shares. In a separate note about Carnival's report, Wieczynski said he continues to favor other cruise operators in the near-term as he gets "impatient" with Carnival, be he still sees value in its shares over the longer-term. Even after lowering his estimates, he believes Carnival's multiple "is compelling enough" to warrant maintaining a Buy rating on the stock, though Wieczynski cut his price target on the stock to $57 from $65.
06/21/19
RHCO
06/21/19
NO CHANGE
Target $65
RHCO
Buy
Carnival price target lowered to $65 from $67 at SunTrust
SunTrust analyst C. Patrick Scholes lowered his price target on Carnival (CCL) to $65 after its Q2 results, below-consensus Q3 guidance, and a cut in its FY19 outlook, also lowering his FY19 and FY20 EPS targets by 17c and 19c to $4.32 and $4.63 respectively. The analyst cites the company's greater exposure to the softer European markets and pressure in its Alaska cruise operations from the increase in capacity. Scholes keeps his Buy rating on Carnival, stating that at near-record-low earnings multiples, it is hard to justify a downgrade, but maintains a more positive relative view on Norwegian Cruise Line (NCLH) and Royal Caribbean (RCL) given their more favorable industry checks.
KPTI Karyopharm
$6.35

-0.085 (-1.32%)

02/28/19
HCWC
02/28/19
NO CHANGE
Target $30
HCWC
Buy
H.C. Wainwright says selinexor expectations not changed by ODAC recommendation
After the FDA's Oncologic Drugs Advisory Committee, or ODAC, voted on February 26 to recommend that the FDA wait for the Phase 3 BOSTON trial results before deciding on selinexor's NDA application, H.C. Wainwright analyst Edward White noted that the decision was not unanimous and said "the FDA typically but does not always follow the ODAC panel's recommendations." It is possible that a delay to wait for the BOSTON data could push out a selinexor launch by one year or more, but the ODAC recommendation is "not changing our expectations," stated White, who keeps a Buy rating and $30 price target on shares of Karyopharm.
03/01/19
JPMS
03/01/19
DOWNGRADE
Target $7
JPMS
Neutral
Karyopharm downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Eric Joseph downgraded Karyopharm Therapeutics to Neutral and lowered his price target for the shares to $7 from $21. The analyst sees a "rocky regulatory road" forward for the company.
03/15/19
WEDB
03/15/19
NO CHANGE
WEDB
Wedbush views Karyopharm 's PDUFA date extension as a positive
Wedbush analyst David Nierengarten maintained an Outperform rating and $6 price target on Karyopharm. In a note titled "FDA Extends PDUFA by Three Months," he said he is inclined to view the extension as a positive for the company "given the negative sentiment on the name and general belief that an April 6, 2019 approval was unlikely."
06/14/19
HCWC
06/14/19
NO CHANGE
Target $29
HCWC
Buy
Karyopharm EHA Phase 1b/2 combination data 'encouraging,' says H.C. Wainwright
H.C. Wainwright analyst Edward White maintained a Buy rating and $29 price target on Karyopharm, saying the company presented "encouraging" early Phase 1b/2 selinexor combination data from the STOMP trial in relapsed or refractory multiple myeloma patients at the European Hematological Association 2019 Annual Meeting. In a research note to investors, White says the updated selinexor with Darzalex data "continues to look good," with efficacy results showing an overall response rate of 73% in Darzalex naive patients versus the EHA abstract data published last month with an ORR of 77%. Looking ahead, White projects revenues of $189M and $241M for selinexor in penta-refractory multiple myeloma and DLBCL, respectively, in 2026. For selinexor in combination multiple myeloma treatment, he forecasts revenues of $332M in 2026, and for selinexor in solid tumors he sees revenues of $241M in 2026.
LAUR Laureate Education
$15.00

-0.365 (-2.38%)

12/11/18
SBSH
12/11/18
INITIATION
Target $19
SBSH
Buy
Laureate Education assumed with a Buy at Citi
Price target $19.

TODAY'S FREE FLY STORIES

COT

Cott Corp.

$12.34

0.05 (0.41%)

20:29
07/23/19
07/23
20:29
07/23/19
20:29
Upgrade
Cott Corp. rating change at Goldman Sachs »

Cott Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 25

    Sep

20:25
07/23/19
07/23
20:25
07/23/19
20:25
Conference/Events
CLSA Asian tech analysts to hold an analyst/industry conference call »

Asian Technology Analysts…

T

AT&T

$32.09

-0.05 (-0.16%)

, BA

Boeing

$372.91

-0.48 (-0.13%)

20:25
07/23/19
07/23
20:25
07/23/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

T

AT&T

$32.09

-0.05 (-0.16%)

BA

Boeing

$372.91

-0.48 (-0.13%)

TMO

Thermo Fisher

$293.82

2.07 (0.71%)

NEE

NextEra Energy

$207.31

-2.05 (-0.98%)

UPS

UPS

$105.24

1.25 (1.20%)

ANTM

Anthem

$302.82

1.04 (0.34%)

CAT

Caterpillar

$138.07

2.87 (2.12%)

BSX

Boston Scientific

$42.80

0.3 (0.71%)

NOC

Northrop Grumman

$324.01

0.93 (0.29%)

GD

General Dynamics

$185.92

1.295 (0.70%)

VFC

VF Corp.

$88.25

1.41 (1.62%)

APH

Amphenol

$98.36

1.185 (1.22%)

HLT

Hilton

$95.18

1.95 (2.09%)

FCX

Freeport McMoRan

$11.65

0.16 (1.39%)

SC

Santander Consumer

$25.74

0.49 (1.94%)

KNX

Knight-Swift

$37.87

0.9 (2.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 30

    Jul

  • 08

    Aug

  • 06

    Sep

  • 09

    Sep

  • 02

    Oct

  • 30

    Oct

  • 13

    Nov

  • 02

    Dec

COT

Cott Corp.

$12.34

0.05 (0.41%)

20:15
07/23/19
07/23
20:15
07/23/19
20:15
Upgrade
Cott Corp. rating change at Goldman Sachs »

Cott Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 25

    Sep

RARX

RA Pharmaceuticals

$33.58

-2.43 (-6.75%)

20:11
07/23/19
07/23
20:11
07/23/19
20:11
Syndicate
RA Pharmaceuticals 4M share Secondary priced at $32.50 »

Jefferies, BMO Capital,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

CUTR

Cutera

$24.40

0.19 (0.78%)

20:04
07/23/19
07/23
20:04
07/23/19
20:04
Hot Stocks
Cutera gets approval of Brazil's ANVISA for truSculpt »

Cutera announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 13

    Nov

ITCI

Intra-Cellular

$8.18

-3.81 (-31.78%)

19:44
07/23/19
07/23
19:44
07/23/19
19:44
Hot Stocks
Intra-Cellular updates on lumateperone info provided to FDA »

Intra-Cellular Therapies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 27

    Sep

SCHW

Charles Schwab

$43.54

0.38 (0.88%)

19:28
07/23/19
07/23
19:28
07/23/19
19:28
Periodicals
Charles Schwab CMO, EVP of investor services to leave, BI says »

Charles Schwab is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

FB

Facebook

$202.38

0.06 (0.03%)

19:26
07/23/19
07/23
19:26
07/23/19
19:26
Periodicals
Facebook CEO must certify compliance under FTC privacy agreement, WSJ says »

Facebook CEO Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

AXP

American Express

$128.20

2.19 (1.74%)

19:24
07/23/19
07/23
19:24
07/23/19
19:24
Periodicals
AmEx to refund $1.6M after finding salespeople misrepresented pricing, WSJ says »

American Express is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

OBE

Obsidian Energy

$1.00

0.0087 (0.88%)

19:22
07/23/19
07/23
19:22
07/23/19
19:22
Hot Stocks
Obsidian Energy regains compliance with NYSE listing standards »

Obsidian Energy received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEFT

Euronet

$165.34

1.22 (0.74%)

19:16
07/23/19
07/23
19:16
07/23/19
19:16
Earnings
Breaking Earnings news story on Euronet »

Euronet Worldwide sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 12

    Aug

  • 25

    Sep

  • 14

    Nov

EEFT

Euronet

$165.34

1.22 (0.74%)

19:16
07/23/19
07/23
19:16
07/23/19
19:16
Earnings
Euronet Worldwide reports Q2 adjusted EPS $1.69, consensus $1.69 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 12

    Aug

  • 25

    Sep

  • 14

    Nov

CALX

Calix

$7.30

0.155 (2.17%)

19:13
07/23/19
07/23
19:13
07/23/19
19:13
Earnings
Calix sees Q3 adjusted EPS 2c-6c, consensus 10c »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

CALX

Calix

$7.30

0.155 (2.17%)

19:12
07/23/19
07/23
19:12
07/23/19
19:12
Earnings
Calix reports Q2 adjusted EPS (1c), consensus (3c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

WE

We Company

$0.00

(0.00%)

19:06
07/23/19
07/23
19:06
07/23/19
19:06
Periodicals
WeWork eyes September IPO, WSJ reports »

WeWork Companies is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIC

Eagle Point Income Company

$0.00

(0.00%)

19:03
07/23/19
07/23
19:03
07/23/19
19:03
Syndicate
Eagle Point Income Company 1.2M share IPO priced at $19.89 »

National Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTS

Tile Shop

$3.08

-0.88 (-22.22%)

18:57
07/23/19
07/23
18:57
07/23/19
18:57
Downgrade
Tile Shop rating change at Telsey Advisory »

Tile Shop downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

AAPL

Apple

$208.85

1.64 (0.79%)

, GOOG

Alphabet

$1,146.62

8.53 (0.75%)

18:57
07/23/19
07/23
18:57
07/23/19
18:57
Periodicals
Apple, Google, Facebook, others petition FCC over VLP Wi-Fi category, Verge says »

Apple (AAPL), Google…

AAPL

Apple

$208.85

1.64 (0.79%)

GOOG

Alphabet

$1,146.62

8.53 (0.75%)

GOOGL

Alphabet Class A

$1,148.77

9.25 (0.81%)

MSFT

Microsoft

$139.29

0.88 (0.64%)

FB

Facebook

$202.38

0.06 (0.03%)

HPQ

HP Inc.

$21.64

0.2 (0.93%)

QCOM

Qualcomm

$74.10

-1.83 (-2.41%)

INTC

Intel

$51.76

0.4 (0.78%)

AVGO

Broadcom

$300.79

4.68 (1.58%)

MRVL

Marvell

$26.50

0.64 (2.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 27

    Oct

JNCE

Jounce Therapeutics

$4.10

-0.1 (-2.38%)

, TER

Teradyne

$48.09

1.26 (2.69%)

18:56
07/23/19
07/23
18:56
07/23/19
18:56
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Jounce…

JNCE

Jounce Therapeutics

$4.10

-0.1 (-2.38%)

TER

Teradyne

$48.09

1.26 (2.69%)

EW

Edwards Lifesciences

$195.47

1.55 (0.80%)

MANH

Manhattan Associates

$72.91

1.16 (1.62%)

SNAP

Snap

$14.85

0.71 (5.02%)

TXN

Texas Instruments

$120.05

1.89 (1.60%)

OLBK

Old Line Bancshares

$26.14

(0.00%)

CSL

Carlisle

$132.30

2.445 (1.88%)

CMG

Chipotle

$740.42

-1.88 (-0.25%)

CNI

Canadian National

$91.05

-0.07 (-0.08%)

DFS

Discover

$84.54

2.205 (2.68%)

NAVI

Navient

$13.71

0.27 (2.01%)

WFC

Wells Fargo

$47.20

0.7 (1.51%)

IRBT

iRobot

$89.64

-2.7 (-2.92%)

RHI

Robert Half

$58.81

1.45 (2.53%)

V

Visa

$180.89

0.34 (0.19%)

SGEN

Seattle Genetics

$75.88

-0.22 (-0.29%)

FB

Facebook

$202.38

0.06 (0.03%)

TWTR

Twitter

$37.90

0.32 (0.85%)

AMZN

Amazon.com

$1,994.44

8.51 (0.43%)

GOOG

Alphabet

$1,146.62

8.53 (0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

  • 30

    Jul

  • 03

    Aug

  • 08

    Aug

  • 21

    Aug

  • 04

    Sep

  • 05

    Sep

  • 09

    Sep

  • 11

    Sep

  • 23

    Sep

  • 25

    Sep

  • 12

    Oct

  • 15

    Oct

  • 27

    Oct

  • 13

    Nov

  • 24

    Jul

DB

Deutsche Bank

$7.95

0.16 (2.05%)

18:45
07/23/19
07/23
18:45
07/23/19
18:45
Periodicals
Deutsche Bank's credit derivatives seen as hard to offload, Reuters says »

Three bank insiders have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 26

    Jul

NHI

National Health Investors

$79.63

0.91 (1.16%)

18:35
07/23/19
07/23
18:35
07/23/19
18:35
Hot Stocks
National Health Investors to invest $7.6M in Colorado community »

National Health Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

RGLS

Regulus

$1.13

-0.07 (-5.83%)

18:32
07/23/19
07/23
18:32
07/23/19
18:32
Hot Stocks
Regulus announces a program update for RGLS4326 »

Regulus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

MPW

Medical Properties Trust

$17.67

0.12 (0.68%)

18:26
07/23/19
07/23
18:26
07/23/19
18:26
Upgrade
Medical Properties Trust rating change at Stifel »

Medical Properties Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAS

Hasbro

$119.22

10.68 (9.84%)

18:24
07/23/19
07/23
18:24
07/23/19
18:24
Hot Stocks
Hasbro CEO: We have a great management team »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.